The FDA approval of iclaprim's QIDP status for both hospital-acquired infection (HAI) indications signals the completion of MTFB's recent £22m fundraising. Next steps, previously confirmed in the IPO documents and supported by the FDA agreement on the Phase 3 plan, are centred on moving into the clinic, recruiting for the ABSSSI trial in H2 2015 and supporting iclaprim's development in these two commercially significant HAI areas.
